Mood changes during bladder cancer treatment with BCG

This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.

This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.

This study is testing a way for people with early-stage bladder cancer to receive their BCG treatment at home, with extra support. It aims to see if doing treatment at home is safe and helpful for patients.

This trial tests whether changing your position while receiving BCG treatment (a liquid medicine placed directly into the bladder) can help it work better. You will wear a fitness tracker for a few days to monitor activity.

This study looks at how the bladder reacts to a standard treatment called BCG, which is given after surgery for early-stage bladder cancer. By checking the tissue and urine before treatment, the study aims to understand if the bladder is ready for BCG therapy, which could help improve outcomes.

This trial tests giving BCG immunotherapy at home instead of in the clinic, to reduce the burden of travel and hospital visits. It may help patients with non-muscle invasive bladder cancer who need BCG treatment after surgery.